Then, we compared the expression profiling of AA1 and AA2 with the melanoma dataset containing 47 patients who received a programmed cell death protein-1 (PD-1) immune checkpoint inhibitor or cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) immune checkpoint inhibitor (38). This evidence concerns the gene CTLA4 and melanoma.